乐虎lehu国际

Collaboration between Uni-Bio Science Group and Swiss company Ypsomed to jointly develop 2nd generation diabetes and osteoporosis products

Collaboration between Uni-Bio Science Group and Swiss company Ypsomed to jointly develop 2nd generation diabetes and osteoporosis products

2020-05-05

View details

Uni-Bio Science Group, Sinopharm Weiqida Pharmaceutical and Suzhou Yingli Medical Technology Build Strategic Partnership on Acarbose Industry Value Chain

Uni-Bio Science Group, Sinopharm Weiqida Pharmaceutical and Suzhou Yingli Medical Technology Build Strategic Partnership on Acarbose Industry Value Chain

2020-04-15

View details

2019 Annual Results Turnover Increased by 54.9% YoY to HK$209.4 million Recording EBITDA of HK$28.4 million Achieved Significant Progress towards Pipeline Product with 2 Product Launches Expected in 2020

2019 Annual Results Turnover Increased by 54.9% YoY to HK$209.4 million Recording EBITDA of HK$28.4 million Achieved Significant Progress towards Pipeline Product with 2 Product Launches Expected in 2020

2020-04-01

View details

2019 Interim Results Announced——Successful Turning Loss into Profit, Strong Release of Market Potential, Sales of key products doubled, Business restructuring completed smoothly

2019 Interim Results Announced——Successful Turning Loss into Profit, Strong Release of Market Potential, Sales of key products doubled, Business restructuring completed smoothly

2019-08-30

View details

Uni-Bio's Products are Once Again Included into the Latest National Medical Insurance Catalogue for 2019, Benefits Future Sales Growth and Long-term Development

Uni-Bio's Products are Once Again Included into the Latest National Medical Insurance Catalogue for 2019, Benefits Future Sales Growth and Long-term Development

Uni-Bio's Products are Once Again Included into the Latest National Medical Insurance Catalogue for 2019, Benefits Future Sales Growth and Long-term Development

2019-08-22

View details

1...
<<
5
6
7
8
9
>>
16

Hot news